PressRelease

PharnexttoPresentLatestScientificDataonitsTwoLeadAssetsat

SeveralInternationalScientificConferences 

  • • DrugcandidatePXT3003,inaPhase3trialforthetreatmentofCharcotMarieToothdiseasetype

    1A,willbehighlightedinsixpostersandtwooralpresentations

  • • Drug candidate PXT864, in clinical development for the treatment of Alzheimer's disease, will be highlightedintwopostersandthreeoralpresentations 

 PARIS,France,7:30am,June11,2018(CEST)-PharnextSA(FR0011191287ALPHA),abiopharmaceutical companypioneeringanewapproachtothedevelopmentofinnovativedrugcombinationsbasedonbigdata genomics and artificial intelligence, today announced its upcoming participation in five international scientificconferencesinJuneandJuly2018throughoutEuropeandtheUnitedStates.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot MarieTooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™indevelopingdrugcombinations, anddiscusstheCompany'sPhase2trialofPXT864forthe treatmentofAlzheimer'sdisease.

Thecompanywillattendthefollowingevents:

EuropeanAcademyofNeurology(EAN)congress June1618,2018inLisbon,Portugal

TwoePosters(oralcommunications)

#EPR1170

A multicenter, doubleblind, placebocontrolled, pivotal phase III study (PLEOCMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003) for CharcotMarie ToothDiseaseType1A(CMT1A).

Presenter:

DrRenéGoedkoop,MD,ChiefMedicalOfficer,Pharnext,France

Room

SessionEPR122/ScreenB12

Date/Time

June16,2018,13:3014:15CEST

#EPR1007

Doubleblind argument for a synergistic therapeutic effect of a fixed lowdose combinationofacamprosateandbaclofeninAlzheimer'sdisease.

Presenter:

DrRenéGoedkoop,MD,ChiefMedicalOfficer,Pharnext,France

Room

SessionEPR101/ScreenA1

Date/Time

June16,2018,13:3014:15CEST

 InternationalCongressonNeuromuscularDiseases(ICNMD)

July610,2018inVienna,Austria

TwoPosters

#545

Baclofen,naltrexoneandsorbitolallcontributetotheefficacyofPXT3003inCMT1Arats.

Authors

T.Prukopetal.

Room

MezzanineFloorGalleryandFoyers

Date/Time

July8,2018,5:15pm6:30pmCEST

#728

Baclofen, naltrexone and sorbitol all contribute to PXT3003induced myelination in CMT1ADRGcocultures.

Authors

N.Choletetal.

Room

SessionRoom1

Date/Time

July8,2018,5:15pm6:30pmCEST

InnovationsandStateoftheArtInDementiaResearchmeeting(ISADR) July1618,2081inValencia,Spain

TwoOralCommunications

Cmaxbased synergistic therapeutic effect on cognitive disability in mild Alzheimer's diseaseafter36weekstreatmentwithbaclofenandacamprosate.

Presenter:

ProfJacquesTouchon,MD,PhD,FacultédeMédecinedeMontpellier,France

Date/Time

July16,2018,11:35am11:55amCEST

ApotentialtritherapyforAlzheimer'sdisease.

Presenter:

DrRodolpheHajj,PhD,ChiefPharmacologyOfficer,Pharnext,France

Date/Time

July16,2018,12:55pm1:15pmCEST

PeripheralNerveSociety(PNS)congress July2225,2018inBaltimore,US

OneOralCommunication

StatusofthePivotalPhaseIIIStudyofPXT3003forCharcotMarieToothType1Adisease (CMT1A).

Presenter:

DrRenéGoedkoop,MD,ChiefMedicalOfficer,Pharnext,France

Date/Time

July23,2018,2.45pm3.00pmEST

FourPosters

#20

Baclofen,naltrexoneandsorbitolallcontributetotheefficacyofPXT3003inCMT1Arats.

Authors

R.Hajjetal.

Session

Session1

Date/Time

July22,2018

#45

StatusofthePivotalPhaseIIIStudyofPXT3003forCharcotMarieToothType1Adisease (CMT1A)

Authors

R.Goedkoopetal.

Session

Session2

Date/Time

July23,2018

#85

Synergy of baclofen, naltrexone and sorbitol (PXT3003) in CharcotMarieTooth Type 1A

(CMT1A)

Authors

J.Laffaireetal..

Session

Session2

Date/Time

July23,2018

#1

Baclofen, naltrexone and sorbitol all contribute to PXT3003induced myelination in CMT1ADRGcocultures

Authors

R.Hajjetal.

Session

Session3

Date/Time

July24,2018

 

Alzheimer'sAssociationInternationalConference(AAIC) July2226,2018inChicago,US

TwoPosters

#P1061

Doubleblind argument for a synergistic therapeutic effect of a fixed lowdose combinationofacamprosateandbaclofeninAlzheimer'sDisease

Authors

JMOrgogozoetal

Session

SessionP101/HallF1

Date/Time

July22,2018,9:30am4:15pmEST

#P3042

PXT864combinationrestorescognitivedeficitsofAlzheimer'smice,eveninanimalswith advanceddiseasethatlostresponsivenesstodonepezil.

Authors

A.Brureauetal.

Session

SessionP302,HallF1

Date/Time

July24,2018,9:30am4:15pmEST

If you are interested in meeting the Pharnext team during either of these events or if you need more informationaboutPharnext'sparticipation,pleasesendanemailtocontact@pharnext.com

AboutPharnext Pharnextisanadvancedclinicalstagebiopharmaceuticalcompanydevelopingnoveltherapeuticsfororphan andcommonneurodegenerativediseasesthatcurrentlylackcurativeand/ordiseasemodifyingtreatments. Pharnexthastwoleadproductsinclinicaldevelopment.PXT3003iscurrentlyinaninternationalPhase3trial for the treatment of CharcotMarieTooth disease type 1A and benefits from orphan drug status in Europe andtheUnitedStates.Theresultsofthistrialareexpectedinthesecondhalfof2018.PXT864hasgenerated positive Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm basedonbiggenomicdataandartificialintelligence:PLEOTHERAPY™.TheCompanyidentifiesanddevelops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robustintellectualproperty.TheCompanywasfoundedbyrenownedscientistsandentrepreneursincluding ProfessorDanielCohen,apioneerinmoderngenomicsandissupportedbyaworldclassscientificteam. 

PharnextislistedonEuronextGrowthStockExchangeinParis(ISINcode:FR0011191287). Formoreinformation,visithttp://www.pharnext.com/    

CONTACTS:

Pharnext

XavierPaoli

ChiefCommercialOfficer

contact@pharnext.com

+33(0)141092230

FinancialCommunication(France)

InvestorRelations(U.S.)

Actifin

SternInvestorRelations,Inc.

StéphaneRuiz

MatthewShinseki

sruiz@actifin.fr

matthew@sternir.com

+33(0)156881115

+12123621200

MediaRelations(Europe)

MediaRelations(U.S.)

UlysseCommunication

RooneyPartners

BrunoArabian

KateL.Barrette

barabian@ulyssecommunication.com

kbarrette@rooneyco.com

+33(0)181709630

+12122230561

InvestorRelations(Europe)

MCServicesAG AnneHennecke anne.hennecke@mcservices.eu +4921152925222  

Attachments

  • Original document
  • Permalink

Disclaimer

Pharnext SA published this content on 11 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 June 2018 05:42:04 UTC